Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs. Analyst David Roman initiated coverage of LivaNova with a Buy rating and price target of $65. The LivaNova Thesis: LivaNova's earnings had been under pressure due to strategic shifts in the company's business and pipeline setbacks. Ro ...

Financial Performance - Net revenue increased by 9.6% on a constant-currency basis to $318.6 million[1,4] - Excluding the ACS segment wind down, net revenue increased 10.8% on a constant-currency basis[94,73] - The company is targeting $95 - $115 million of adjusted free cash flow for full-year 2024[11] - LTM adjusted free cash flow was $139.9 million with an LTM adjusted free cash flow conversion ratio of 79%[11] Segment Performance - Cardiopulmonary revenue increased 14.5% to $173.7 million, driven by strong demand for consumables and Essenz sales[80,81] - Neuromodulation revenue increased 7.8% to $142.9 million, with growth across all regions[83,84] - United States Cardiopulmonary revenue increased 29.7% to $64.9 million[77] - United States Neuromodulation revenue increased 7.3% to $111.7 million[77] Guidance - The company is raising full-year guidance for net revenue growth to 7-8% and net revenue growth, excluding ACS, to 9-10%[31] - The company is raising full-year guidance for adjusted diluted EPS to $3.10 - $3.20[31]

LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 17.72%. A quarter ago, it was expected that this medical technology company would post earnings of $0.45 per share when it actually produced earnings of $0.73, delivering a surprise of 62.22%. Over the last four quarters, ...

EXHIBIT 99.1 London, July 31, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. • Announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study on June 6, 2024. Following additional in-depth analyses of the data, intends to pursue U.S. Centers for Medicare and Medicaid Services coverage for VNS Therapy™ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its cha ...

| --- | --- | --- | --- | --- | |------------------------------|-------|-------|-------|-------| | | | | | | | Liva Nova First Quarter 2024 | | | | | | Earnings Update | | | | | | May 1, 2024 | | | | | Safe Harbor 2 forward-looking statements, which are made only as of the date of this material. 3 • Trademarks for LivaNova's Neuromodulation systems, the VNS Therapy™ System, the VITARIA™ System and LivaNova's proprietary pulse generator products: Model 102 (Pulse™), Model 102R (Pulse Duo™), Model 103 (Demipu ...

LivaNova (LIVN) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.22%. A quarter ago, it was expected that this medical technology company would post earnings of $0.79 per share when it actually produced earnings of $0.87, delivering a surprise of 10.13%.Over the last four quarters, ...

EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2024 Results London, May 1, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) "In the first quarter, LivaNova achieved double-digit revenue and operating income growth in both the Cardiopulmonary and Neuromodulation segments," said Vladimir Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its charter) England and Wales ................... 98-126815 ...

Financial Data and Key Metrics - Cardiopulmonary revenue for the full year was $589 million, growing 18% year-over-year, with an expected growth of 6% to 7% for 2024 [1] - Adjusted operating income was $48 million in Q4 2023, compared to $47 million in Q4 2022, with a margin of 16% versus 17% in the prior year [5] - Adjusted diluted earnings per share (EPS) was $0.87 in Q4 2023, up from $0.81 in Q4 2022 [5] - Cash balance at year-end 2023 was $267 million, up from $214 million in 2022, while total debt increased to $587 million from $542 million [26] - Adjusted free cash flow for Q4 2023 was $60 million, up from $31 million in the prior year, driven by higher income and improved working capital [26] Business Line Performance - Cardiopulmonary segment revenue in Q4 2023 was $162 million, a 17% increase year-over-year, driven by strong Essenz sales in Europe and the U.S. [7] - Heart-lung machine (HLM) revenue grew over 40% in Q4 2023, while oxygenator revenue grew in the mid-single digits, despite capacity constraints [7] - Epilepsy revenue increased 8% in Q4 2023 compared to Q4 2022, with 856 new patient implants (6% growth) and 1982 replacement implants (10% growth) [1] - ACS revenue was $10 million in Q4 2023, up 5% year-over-year, with full-year revenue of $40 million, growing 3% [8] - DTD revenue for Q4 2023 was $2 million, with full-year revenue of $7 million, and 2024 revenue expected to remain at $7 million [8] Market Performance - U.S. epilepsy revenue grew 8% year-over-year in Q4 2023, with 3300 new patient implants for the full year, representing 7% growth [21] - Europe and rest of the world epilepsy revenue grew 7% year-over-year in Q4 2023, with full-year epilepsy revenue increasing 10% [21] - Foreign exchange had a favorable impact of $3 million (1% of revenue) in Q4 2023 [22] Strategic Direction and Industry Competition - The company is winding down the ACS segment, with a pretax non-cash impairment charge of $103 million in Q4 2023, and expects additional restructuring charges of $15 million to $20 million in 2024 [2] - The company is reorganizing its operating and reporting structure from three to two segments: cardiopulmonary and neuromodulation, effective Q1 2024 [2] - The company is focusing on core businesses (cardiopulmonary and neuromodulation) for growth and value creation, with the ACS wind-down expected to positively contribute to adjusted operating income in 2024 [13] - The company is addressing oxygenator capacity constraints, with improvements expected to benefit production in the second half of 2024 [39] Management Commentary on Operating Environment and Future Outlook - The company expects 2024 revenue growth of 4% to 5% on a constant currency basis, or 6% to 7% excluding the ACS business [37] - Adjusted operating income is expected to grow approximately 25% in 2024, with a 300 basis point improvement in adjusted operating income margin [106] - The company anticipates a full-year adjusted effective tax rate of 21% in 2024, with an unfavorable impact of $0.45 on EPS [88] - Adjusted free cash flow for 2024 is expected to be in the range of $95 million to $115 million, with capital spending forecasted at $60 million [27] Other Important Information - The company incurred $2.6 million in costs related to a cybersecurity incident in Q4 2023, primarily for external experts, legal counsel, and system restoration [36] - The company is awaiting a binding decision from the European Court of Justice regarding the SNIA litigation, with a decision expected in 2024 [70] Q&A Summary Question: Competitive situation in the oxygenator market and capacity expansion [30] - The company noted no significant changes in competition, with one smaller competitor dissipating and a major competitor yet to return to the market [28] - Capacity improvements are expected to benefit production in the second half of 2024 [39] Question: Guidance and earnings bridge for 2024 [32] - The ACS wind-down is expected to result in significant improvements in 2024, with full benefits realized in 2025 [33] - The company expects a $0.10 EPS impact from the ACS wind-down and a $0.35 EPS impact from reduced R&D spend related to the heart failure program [37] Question: Oxygenator market share and stickiness [40] - The company estimates its market share has increased to the mid-30s, with half of its high-volume business being tender-based [41] Question: Tax rate and stock-based compensation [43] - The company expects a 21% adjusted effective tax rate in 2024, driven by jurisdictional profitability [43] - The company will follow up on the impact of stock-based compensation on the tax rate [99] Question: Cybersecurity incident impact on revenue [54] - The cybersecurity incident impacted oxygenator production, resulting in a loss of about one week of production, but the revenue impact was not material [57] Question: Neuromodulation segment growth and sustainability [58] - The company expects mid-single-digit growth in new patient implants and low-single-digit growth in replacements for 2024, with overall segment growth of 6% to 7% [64] Question: STRAP plan and Vlad's priorities [62] - The company will provide updates on the STRAP plan in the first half of 2024, with Vlad expected to bring forward new ideas and strategies [65] Question: Gross margin benefit from Essenz [68] - Essenz is expected to contribute to a 100 basis point improvement in gross margin in 2024 [63] Question: Depression study and OSA trial [97] - The company expects to receive 12-month follow-up data for the depression study in June 2024, with publication expected by late 2024 [8] - OSA trial enrollment is progressing, with 25 study sites recruiting patients [9] Question: Italian reserve and litigation timeline [114] - The company is awaiting a binding decision from the European Court of Justice in 2024, with a final decision from the Italian Supreme Court expected in 2025 [70] Question: CAPEX increase and investments [86] - The company is increasing CAPEX to $60 million in 2024, focusing on oxygenator capacity, IT infrastructure, and ERP system modernization [82][110]